A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria

Completed · Phase 3

Conditions studied: Paroxysmal Nocturnal Hemoglobinuria

In brief

The purpose of this study was to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy of ravulizumab in pediatric participants with paroxysmal nocturnal hemoglobinuria (PNH).

Key facts

Study ID

NCT03406507

Run by

Alexion Pharmaceuticals, Inc.

People needed

13

Starts

2018-02-22

Expected to finish

2022-08-25

Last updated by the study team

2023-03-27

Who can join

Age: any, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants from birth up to <18 years of age and weighing ≥ 5 kilograms at the time of consent.
• PNH diagnosis confirmed by documented high-sensitivity flow cytometry.
• Presence of 1 or more of the following PNH-related signs or symptoms within 3 months of Screening: fatigue, hemoglobinuria, abdominal pain, shortness of breath (dyspnea), anemia, history of a major adverse vascular event (including thrombosis), dysphagia, or erectile dysfunction; or history of packed red blood cell transfusion due to PNH.
• Lactate dehydrogenase (LDH) level ≥ 1.5 × upper limit of normal (ULN) for participants not being treated with eculizumab at screening and LDH level ≤ 1.5 × ULN for participants taking eculizumab.
• Documented meningococcal vaccination not more than 3 years prior to dosing, and vaccination against Streptococcus pneumoniae and Haemophilus influenzae.
• Female participants of childbearing potential must use highly effective contraception starting at screening and continuing until at least 8 months after the last dose of ravulizumab.

You may not qualify if…

• History of bone marrow transplantation.
• History of or ongoing major cardiac, pulmonary, renal, endocrine, or hepatic disease that, in the opinion of the investigator or sponsor, would preclude participation.
• Unstable medical conditions (for example, myocardial ischemia, active gastrointestinal bleed, severe congestive heart failure, anticipated need for major surgery within 6 months of randomization, coexisting chronic anemia unrelated to PNH).
• Females who are pregnant or breastfeeding or who have a positive pregnancy test at screening or Day 1.
• Participation in another interventional clinical study or use of any experimental therapy within 30 days before initiation of study drug on Day 1 in this study or within 5 half-lives of that investigational product, whichever is greater.

Where it is running

• Clinical Trial Site — Atlanta, Georgia, United States
• Clinical Trial Site — Milwaukee, Wisconsin, United States
• Clinical Trial Site — Paris, France
• Clinical Trial Site — Utrecht, Netherlands
• Clinical Trial Site — Oslo, Norway
• Clinical Trial Site — Moscow, Russia
• Clinical Trial Site — Saint Petersburg, Russia
• Clinical Trial Site — Leeds, United Kingdom
• Clinical Trial Site — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.